Most cited papers in Viral Infections and Outbreaks Research
What are the most cited papers in Viral Infections and Outbreaks Research?
The most cited paper in Viral Infections and Outbreaks Research is "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor" (Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder et al., 2020), with 21,493 citations. Next come "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein" (9,155) and "The Danger Model: A Renewed Sense of Self" (4,209).
Showing 50 of 100 papers. Every paper with more than 914 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder et al. · Cell | 8 Mar 2020 | 21,493 |
| 2 | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell | 9 Mar 2020 | 9,155 |
| 3 | The Danger Model: A Renewed Sense of Self Polly Matzinger · Science | 12 Apr 2002 | 4,209 |
| 4 | How will country-based mitigation measures influence the course of the COVID-19 epidemic? Roy Malcolm Anderson, Hans Heesterbeek, Don Klinkenberg et al. · The Lancet | Mar 2020 | 3,922 |
| 5 | Cell entry mechanisms of SARS-CoV-2 Jian Shang, Yushun Wan, Chuming Luo et al. · Proceedings of the National Academy of Sciences | 6 May 2020 | 3,473 |
| 6 | Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Xiuyuan Ou, Yan Liu, Xiaobo Lei et al. · Nature Communications | 27 Mar 2020 | 3,412 |
| 7 | Infectious Diseases Society of America J. F. Enders · The Journal of Infectious Diseases | Mar 1969 | 3,307 |
| 8 | Zika Virus Outbreak on Yap Island, Federated States of Micronesia Mark R. Duffy, Tai-Ho Chen, W. Thane Hancock et al. · New England Journal of Medicine | 10 Jun 2009 | 3,232 |
| 9 | Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand Supachai Rerks‐Ngarm et al. · New England Journal of Medicine | 20 Oct 2009 | 3,067 |
| 10 | Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak Annelies Wilder‐Smith, David O. Freedman · Journal of Travel Medicine | 10 Feb 2020 | 2,847 |
| 11 | Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts Joel Hellewell et al. · The Lancet Global Health | 29 Feb 2020 | 2,830 |
| 12 | Data, disease and diplomacy: GISAID's innovative contribution to global health Stefan Elbe, Gemma Buckland‐Merrett · Global Challenges | 2017 | 2,318 |
| 13 | Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Carlos Augusto Gomes · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) | 24 Mar 2020 | 2,230 |
| 14 | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 John Patrick Thornhill et al. · New England Journal of Medicine | 21 Jul 2022 | 2,219 |
| 15 | Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system Rolf M. Zinkernagel, Peter C. Doherty · Nature | Apr 1974 | 2,108 |
| 16 | Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus Oliver J. Brady, Peter W. Gething, Samir Bhatt et al. · PLoS neglected tropical diseases | 7 Aug 2012 | 1,935 |
| 17 | Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Raquel Pricilla e Silva Viana et al. · Nature | 7 Jan 2022 | 1,926 |
| 18 | Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine Timo Vesikari et al. · New England Journal of Medicine | 4 Jan 2006 | 1,890 |
| 19 | Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction R. S. Lanciotti, Charles H. Calisher, Duane J. Gubler et al. · Journal of Clinical Microbiology | Mar 1992 | 1,860 |
| 20 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Guangdi Li, Erik De Clercq · Nature Reviews Drug Discovery | 10 Feb 2020 | 1,843 |
| 21 | Detection of a SARS-CoV-2 variant of concern in South Africa Houriiyah Tegally et al. · Nature | 9 Mar 2021 | 1,837 |
| 22 | Trained Immunity: A Memory for Innate Host Defense Mihai G. Netea, Jessica Quintin, Jos W. M. van der Meer · Cell Host & Microbe | May 2011 | 1,711 |
| 23 | QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1 Sander Greenland · Epidemiologic Reviews | 1987 | 1,675 |
| 24 | A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics Sabué Mulangu, Lori Elizabeth Dodd, Richard T. Davey et al. · New England Journal of Medicine | 27 Nov 2019 | 1,664 |
| 25 | Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity David W. Vaughn, Sharone Green, Siripen Kalayanarooj et al. · The Journal of Infectious Diseases | 2000 | 1,658 |
| 26 | Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Travis K. Warren et al. · Nature | 2 Mar 2016 | 1,620 |
| 27 | Fruit bats as reservoirs of Ebola virus Eric Maurice Leroy, Brice Kumulungui, Xavier Pourrut et al. · Nature | 30 Nov 2005 | 1,618 |
| 28 | Real-time, portable genome sequencing for Ebola surveillance Joshua C Quick et al. · Nature | Feb 2016 | 1,600 |
| 29 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity Leticia P. Corrales, Laura Hix Glickman, Sarah M. McWhirter et al. · Cell Reports | May 2015 | 1,558 |
| 30 | Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil Nuno Rodrigues Faria et al. · Science | 14 Apr 2021 | 1,553 |
| 31 | Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Wilfredo Francisco Garcia-Beltran, Evan Christopher Lam, Kerri St. Denis et al. · Cell | 12 Mar 2021 | 1,548 |
| 32 | A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment Vincent J. Munster, Marion Koopmans, Neeltje van Doremalen et al. · New England Journal of Medicine | 24 Jan 2020 | 1,510 |
| 33 | Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak Tao Zhang, Qunfu Wu, Zhigang Zhang · Current Biology | 19 Mar 2020 | 1,503 |
| 34 | Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions Biao Tang, Xia Wang, Qian Li et al. · Journal of Clinical Medicine | 7 Feb 2020 | 1,486 |
| 35 | Return of the Coronavirus: 2019-nCoV Lisa E. Gralinski, Vineet D. Menachery · Viruses | 24 Jan 2020 | 1,438 |
| 36 | Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail Johanna K. Hansen et al. · Science | 15 Jun 2020 | 1,436 |
| 37 | Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) Hiroshi Nishiura, Tetsuro Kobayashi, Takeshi Miyama et al. · International Journal of Infectious Diseases | 13 Mar 2020 | 1,430 |
| 38 | Tularemia as a Biological Weapon David T. Dennis, Thomas V. Inglesby, Donald A. Henderson et al. · JAMA | 6 Jun 2001 | 1,418 |
| 39 | Emergence of Zaire Ebola Virus Disease in Guinea Sylvain Baize et al. · New England Journal of Medicine | 16 Apr 2014 | 1,399 |
| 40 | Ebola haemorrhagic fever Heinz Feldmann, Thomas W. Geisbert · The Lancet | 16 Nov 2010 | 1,389 |
| 41 | The Outbreak of West Nile Virus Infection in the New York City Area in 1999 Denis Nash, Farzad Mostashari, Annie D. Fine et al. · New England Journal of Medicine | 14 Jun 2001 | 1,387 |
| 42 | Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment Olivier J. Wouters, Kenneth C. Shadlen, Maximilian Salcher‐Konrad et al. · The Lancet | 15 Feb 2021 | 1,376 |
| 43 | Ebola virus entry requires the cholesterol transporter Niemann–Pick C1 Jan E. Carette, Matthijs Raaben, Anthony Wong et al. · Nature | 24 Aug 2011 | 1,372 |
| 44 | Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Philip J. M. Brouwer et al. · Science | 15 Jun 2020 | 1,356 |
| 45 | Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China Juanjuan Zhang, Maria Litvinova, Yuxia Liang et al. · Science | 29 Apr 2020 | 1,348 |
| 46 | Updated Global Burden of Cholera in Endemic Countries Mohammad Ali, Allyson R. Nelson, Anna Lena Lopez et al. · PLoS neglected tropical diseases | 4 Jun 2015 | 1,339 |
| 47 | Evidence of Airborne Transmission of the Severe Acute Respiratory Syndrome Virus Ignatius T. S. Yu, Yuguo Li, Tze Wai Wong et al. · New England Journal of Medicine | 21 Apr 2004 | 1,307 |
| 48 | Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study Marius Gilbert, Giulia Pullano, Francesco Pinotti et al. · The Lancet | 20 Feb 2020 | 1,302 |
| 49 | Clinical features and management of human monkeypox: a retrospective observational study in the UK Hugh Adler et al. · The Lancet Infectious Diseases | 24 May 2022 | 1,299 |
| 50 | Dengue Scott B. Halstead · The Lancet | Nov 2007 | 1,295 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.